Clinical Trials in Philadelphia

Showing 981-1000 of 9,968 trials

FTT PET/CT in Pancreatic Neuroendocrine Tumors

NCT07114939

A pilot study to evaluate the expression of PARP-1 in patients with pancreatic neuroendocrine tumors will be conducted. This will be done via the use of a novel PET imaging agent, \[18F\]FluorThanatrace (\[18F\]FTT). A total of 12 patients will be enrolled. Patients will undergo a study imaging assessment using a whole-body PET CT scanner. Dynamic images will be obtained beginning immediately prior to the administration of 10 mCi of \[18F\]FTT (±20%) for a total of 60 minutes. A static scan may subsequently be obtained up to 90 minutes post radiotracer injection, per the PI's discretion. \[18F\]FTT uptake will be measured on the PET scan and correlated with two molecular outcomes.

Neuroendocrine Carcinoma MetastaticPancreatic Tumors

Abramson Cancer Center at Penn Medicine12 participantsStarted Oct 2025

Philadelphia, Pennsylvania, United States

Active Not RecruitingPhase 2< 1 mile

A Study of Durvalumab Alone and Durvalumab+Olaparib in Advanced, Platinum-Ineligible Bladder Cancer (BAYOU)

NCT03459846

A Phase II, Randomized, Multi-Center, Double-Blind, Comparative Global Study to Determine the Efficacy and Safety of Durvalumab in Combination With Olaparib for First-Line Treatment in Platinum-Ineligible Patients With Unresectable Stage IV Urothelial Cancer

Urinary Bladder Neoplasms

AstraZeneca154 participantsStarted Mar 2018

Birmingham, Alabama, United States • Goodyear, Arizona, United States • Fort Myers, Florida, United States +41 more locations

FTT PET/CT in Pancreatic Neuroendocrine Tumors

A Study of Durvalumab Alone and Durvalumab+Olaparib in Advanced, Platinum-Ineligible Bladder Cancer (BAYOU)

Find Trials by Condition in Philadelphia

Safety and Effectiveness of the Globe® Pulsed Field System for Treating Patients With Symptomatic Paroxysmal or Persistent Atrial Fibrillation

Supporting Evidence-based Responses to Emotional Needs in Emphysema

TACE With or Without SBRT as Bridging Therapy for Pre-transplant HCC Patients

Metformin Hydrochloride and Doxycycline in Treating Patients With Head and Neck Squamous Cell Carcinoma

A Study to Evaluate the Efficacy and Safety of ABC008 for Inclusion Body Myositis

Adaptive Radiation Planning for the Reduction of Radiation-Induced Toxicity in Patients With Stage II-IV Non-small Cell Lung Cancer

Abbott Structural Heart Device Registry

A Study of Pembrolizumab Plus Local Chemotherapy Using Isolated Limb Infusion (ILI) for Patients With Sarcoma in the Arm or Leg

Evaluation of Treatment Response Using Multiparametric MRI After Prostate Radiotherapy

Combination Chemotherapy With or Without Autologous Stem Cell Transplant in Treating Patients With Central Nervous System B-Cell Lymphoma

A Study of FX-909 in Patients With Advanced Solid Malignancies, Including Advanced Urothelial Carcinoma

Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1)

A Clinical Trial of PRAX-562 in Subjects With Developmental and Epileptic Encephalopathies (DEE)

Study to Compare Efficacy, Safety, and Immunogenicity of LUBT010 (Proposed Ranibizumab Biosimilar) and Lucentis® in Patients With Neovascular AMD

A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma

Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer

Tuvusertib (M1774) in Participants With Metastatic or Locally Advanced Unresectable Solid Tumors (DDRiver Solid Tumors 301)

Prospective Study Evaluating the Treatment Outcomes for Localised Recurrent, Resectable Retroperitoneal Liposarcoma